Author

Lucie Lagadec

Centre National de la Recherche Scientifique

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Bérangère LombardiD· 1 shared Caroline RobertiD· 1 shared Cédric MessaoudiiD· 1 shared Damarys LoewiD· 1 shared Dorothée BaïlleiD· 1 shared Eva GuériniD· 1 shared Hélène Lecourt· 1 shared Hussein Abou‐HamdaniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bérangère LombardORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy

Lucilla Fabbri, Lucie Lagadec, Eva Guérin, Hélène Lecourt, Dorothée Baïlle, Laetitia Besse, Cédric Messaoudi, Laurent Désaubry, Hussein Abou‐Hamdan, Sévérine Roy, Bérangère Lombard, Damarys Loew, Jean‐Yves Scoazec, Caroline Robert, Stéphan Vagner

This study shows that translational control of 53BP1 mRNA regulates adaptive mutability in melanoma cells, and targeting eIF4A reduces resistance to BRAF/MEK inhibitors.

EMBO Molecular Medicine · Jul 20, 2026Peer-reviewedCancer Biology